XPS™ contract signed with leading hospital in Alabama

The XPS™ is the first sold to Alabama, USA. Delivery and installation of the
XPS™ will take place in July 2016.
University of Alabama Birmingham is responsible for the only well-developed lung
transplantation program in Alabama. The center has decided to purchase a XPS™ to
establish an EVLP program and further develop the lung transplantation program.

XPS™ is the only CE-marked and FDA approved (Humanitarian Device Exemptions
approval) integrated system on the market today which gives the user the
flexibility to perform evaluation of lungs before transplantation through a
standardized and simplified procedure. Use of XPS™ has shown good clinical
results at 18 clinics in the US, many of which are national leaders in their
field. Six XPS™ contracts have now been signed by European clinics, giving them
access to the XPS™ system for lung transplantation, and the company notes
continuing high interest for the XPS™ in the US and in Europe.

“We are delighted and proud that EVLP with XPS™ and STEEN Solution™ will be used
for evaluating lungs for transplantation at the very well reputed University of
Alabama Birmingham. This is the hospital performing lung transplantation in the
state of Alabama, USA. The company sees a continued high interest from American
and European clinics to set up XVIVOs XPS ™ system to facilitate lung evaluation
with the aim of using more of the donated lungs”, says Magnus Nilsson, CEO of
XVIVO Perfusion.

June 17, 2016
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101,
christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on June17, 2016 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ First North premier and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com